Opportunity Information: Apply for RFA HG 23 005
The Data Integration and Statistical Analysis Methods (DISAM) funding opportunity (RFA-HG-23-005) is a National Institutes of Health (NIH) cooperative agreement (U01; clinical trial not allowed) focused on creating new, broadly usable statistical and computational methods for analyzing developmental functional genomics datasets. The core scientific target is to enable stronger, more generalizable analysis of data being produced by the human Developmental Genotype-Expression (dGTEx) project and the related non-human primate developmental GTEx effort (NHP dGTEx). In practical terms, NIH is looking for method development that helps researchers draw more reliable conclusions from complex, high-dimensional developmental data, especially where gene expression, regulation, genotype, tissue context, and time/developmental stage are all changing at once.
A major theme of the NOFO is methods that can quantify how genetic variation influences development. That includes approaches that can detect and model developmental stage-specific effects (for example, eQTLs or regulatory effects that appear only during certain windows), methods that handle longitudinal or pseudo-temporal structure across developmental time, and strategies to separate true developmental signals from technical artifacts or shifting cell-type composition. Another emphasized area is comparing gene expression and gene regulation across multiple tissues and across time points, which typically requires models that can borrow strength across conditions, address missingness and uneven sampling, and control error rates when tests are repeated across many tissues, stages, and molecular readouts.
The opportunity also strongly encourages work that uses comparative genomics to clarify developmental and evolutionary processes, particularly by integrating human and non-human primate data. This can include methods for cross-species alignment of regulatory features, models that account for species-specific differences in developmental timing (heterochrony), and statistical frameworks for identifying conserved versus divergent regulatory programs during development. NIH is also interested in tools that connect these developmental GTEx-style resources with existing tissue and cell atlas efforts, implying a need for integrative methods that can harmonize datasets generated with different platforms, resolutions (bulk vs single-cell), or annotation standards. Projects that make it easier to integrate developmental transcriptomic and regulatory data with broader atlas initiatives, while maintaining interpretability and reproducibility, fit squarely within the intent of DISAM.
From an applicant standpoint, the NOFO is intentionally open: eligibility is not restricted to investigators already affiliated with dGTEx or NHP dGTEx, and teams completely outside those consortia are welcome. The eligible applicant pool is broad and includes many institution types and organizational categories. Beyond typical academic and research institutions, eligible applicants include federal agencies, state and local governments, tribal governments and tribal organizations, independent school districts, public housing authorities/Indian housing authorities, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses. The announcement also explicitly highlights additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based and community-based organizations, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) entities.
Administratively, this is a discretionary NIH opportunity using the cooperative agreement mechanism, which typically indicates a more interactive relationship with NIH staff compared with a standard research project grant (while still requiring investigator-led science). The original application due date listed is November 20, 2023, and the award ceiling is $400,000 (as provided in the source data). The opportunity is associated with CFDA numbers 93.172, 93.242, and 93.865. Overall, DISAM is aimed at advancing the statistical and data-integration toolkit needed to unlock developmental insights from large-scale genotype and gene regulation resources, with particular emphasis on methods that generalize across tissues, time, individuals, and even species, and that can plug into the larger ecosystem of human tissue and cell atlas initiatives.Apply for RFA HG 23 005
- The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "Data Integration and Statistical Analysis Methods (DISAM) (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172, 93.242, 93.865.
- This funding opportunity was created on 2023-04-18.
- Applicants must submit their applications by 2023-11-20. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $400,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the DISAM funding opportunity?
Data Integration and Statistical Analysis Methods (DISAM) is an NIH funding opportunity (RFA-HG-23-005) that supports the creation of new, broadly usable statistical and computational methods for analyzing developmental functional genomics datasets.
What type of NIH award is DISAM?
DISAM uses the NIH cooperative agreement mechanism (U01). This structure typically involves a more interactive relationship with NIH staff than a standard research project grant, while keeping the scientific direction investigator-led.
Are clinical trials allowed under this opportunity?
No. The notice specifies "clinical trial not allowed."
What scientific problem is DISAM trying to solve?
The opportunity targets method development that makes it easier to draw reliable, generalizable conclusions from complex, high-dimensional developmental data where genotype, gene expression and regulation, tissue context, and developmental stage/time are changing at once.
Which datasets or projects are most central to the NOFO?
The core scientific target is enabling stronger analysis of data produced by the human Developmental Genotype-Expression (dGTEx) project and the related non-human primate developmental GTEx effort (NHP dGTEx).
Do applicants need to be affiliated with dGTEx or NHP dGTEx to apply?
No. Eligibility is intentionally open, and investigators and teams outside those consortia are explicitly welcome.
What kinds of methods is NIH looking for?
NIH is looking for broadly usable statistical and computational methods for developmental functional genomics, especially methods that generalize across tissues, time, individuals, and potentially across species.
Is quantifying how genetic variation influences development a priority area?
Yes. A major theme is methods that quantify how genetic variation influences development, including approaches that can detect and model developmental stage-specific effects.
What does "developmental stage-specific effects" mean in this context?
It refers to genetic or regulatory effects (for example, eQTLs or regulatory effects) that may appear only during certain developmental windows or stages rather than being constant across time.
Are longitudinal or pseudo-temporal methods relevant to DISAM?
Yes. The NOFO emphasizes methods that can handle longitudinal or pseudo-temporal structure across developmental time.
Does the opportunity address technical artifacts and cell-type composition changes?
Yes. NIH specifically highlights the need for strategies that separate true developmental signals from technical artifacts or shifting cell-type composition.
Is cross-tissue analysis part of the scope?
Yes. An emphasized area is comparing gene expression and gene regulation across multiple tissues and across time points.
What methodological challenges does NIH call out for multi-tissue and multi-timepoint work?
The description highlights needs such as borrowing strength across conditions, addressing missingness and uneven sampling, and controlling error rates when tests are repeated across many tissues, stages, and molecular readouts.
Does DISAM encourage comparative genomics and cross-species integration?
Yes. The opportunity strongly encourages comparative genomics approaches that integrate human and non-human primate data to clarify developmental and evolutionary processes.
What are examples of cross-species method development interests mentioned?
Examples include cross-species alignment of regulatory features, models that account for species-specific differences in developmental timing (heterochrony), and frameworks to identify conserved versus divergent regulatory programs during development.
Is integrating developmental GTEx-style resources with tissue/cell atlas efforts within scope?
Yes. NIH expresses interest in tools that connect developmental GTEx-style resources with existing tissue and cell atlas efforts.
What integration issues are implied when connecting to atlas initiatives?
The NOFO implies a need for methods that can harmonize datasets produced with different platforms, different resolutions (bulk vs single-cell), or different annotation standards, while maintaining interpretability and reproducibility.
Who is eligible to apply?
The eligible applicant pool is broad and includes academic and research institutions as well as federal agencies, state and local governments, tribal governments and tribal organizations, independent school districts, public housing authorities/Indian housing authorities, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses.
Are non-U.S. (foreign) entities eligible?
Yes. The announcement explicitly includes non-U.S. (foreign) entities as eligible applicants.
Are U.S. territories or possessions included in the eligible applicant categories?
Yes. U.S. territories or possessions are explicitly highlighted among eligible groups.
Does the NOFO explicitly encourage applications from specific institution types?
Yes. It highlights additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based and community-based organizations, and regional organizations.
What is the application due date listed in the provided information?
The original application due date listed is November 20, 2023.
What is the award ceiling mentioned?
The award ceiling is listed as $400,000 (as provided in the source data).
Which CFDA numbers are associated with DISAM?
The opportunity is associated with CFDA numbers 93.172, 93.242, and 93.865.
What is the overall intent of DISAM in plain terms?
DISAM aims to advance statistical analysis and data-integration methods that help researchers extract developmental insights from large-scale genotype and gene regulation resources, with emphasis on methods that work across tissues and time, remain robust to common confounders, and can extend to cross-species comparisons and atlas-scale integration.
Browse more opportunities from the same category: Health, Income Security and Social Services
Next opportunity: Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
Previous opportunity: Bureau of Land Management Alaska IIJA Fisheries and Aquatic Resource Management
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HG 23 005
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HG 23 005) also looked into and applied for these:
| Funding Opportunity |
|---|
| Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) Apply for PAR 23 180 Funding Number: PAR 23 180 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Specialized Centers for Research on Health Disparities in Uterine Leiomyoma (SCHDUL) (P50 Clinical Trial Not Allowed) Apply for RFA HD 24 005 Funding Number: RFA HD 24 005 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,000,000 |
| Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed) Apply for PAR 23 193 Funding Number: PAR 23 193 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATCH-IN) Implementation Science Coordinating Center (UM2 Clinical Trial Optional) Apply for RFA HD 24 009 Funding Number: RFA HD 24 009 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,250,000 |
| National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50 Clinical Trial Optional) Apply for RFA HD 24 010 Funding Number: RFA HD 24 010 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,100,000 |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional) Apply for RFA MH 24 160 Funding Number: RFA MH 24 160 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R21 Clinical Trial Optional) Apply for RFA MH 24 161 Funding Number: RFA MH 24 161 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Diagnostic Centers of Excellence for the Undiagnosed Diseases Network (U01 Clinical Trial Not Allowed) Apply for PAR 23 289 Funding Number: PAR 23 289 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $500,000 |
| BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional) Apply for RFA MH 24 190 Funding Number: RFA MH 24 190 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $300,000 |
| Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed) Apply for PAR 23 296 Funding Number: PAR 23 296 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $275,000 |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R21 Clinical Trial Optional) Apply for RFA MH 24 331 Funding Number: RFA MH 24 331 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $275,000 |
| Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed) Apply for PAR 23 297 Funding Number: PAR 23 297 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional) Apply for RFA MH 24 330 Funding Number: RFA MH 24 330 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional) Apply for RFA NS 23 032 Funding Number: RFA NS 23 032 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,000,000 |
| Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed) Apply for PAR 24 045 Funding Number: PAR 24 045 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $275,000 |
| HEAL Initiative: Limited Competition: Data Coordinating Center for Completion of the Outcomes of Babies with Opioid Exposure (OBOE) Study (U24 Clinical Trial Not Allowed) Apply for RFA HD 24 015 Funding Number: RFA HD 24 015 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Information and Practice Needs Relevant to Late Talking Children (R21 Clinical Trial Not Allowed) Apply for PAR 24 046 Funding Number: PAR 24 046 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $275,000 |
| HEAL Initiative: Limited Competition: Clinical Centers for Completion of the Outcomes of Babies with Opioid Exposure (OBOE) Study (UG1 Clinical Trial Not Allowed) Apply for RFA HD 24 014 Funding Number: RFA HD 24 014 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $100,000 |
| Down Syndrome Cohort Research Sites (DS-CRS) for the Down Syndrome Cohort Study Program (DS-CDP) across the lifespan for the INCLUDE Project (U01 Clinical Trial Not Allowed) Apply for RFA OD 24 003 Funding Number: RFA OD 24 003 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $300,000 |
| Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 23 061 Funding Number: RFA AI 23 061 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $850,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 23 005", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
